medigraphic.com
Órgano de Difusión de la Asociación Académica Panamericana de Medicina Familiar A.C.

2021, Number 2

<< Back Next >>

Arch Med Fam 2021; 23 (2)

Quality of Life of Patients with Helicobacter Pylori Eradication Therapy and Probiotics

Morales-Castillo P, Márquez-Celedonio FG, Villagómez-García I, Villegas-Domínguez JE

Language: Spanish
References: 34
Page: 67-74
PDF size: 360.11 Kb.


ABSTRACT

Objective: Compare quality of life of patients with complementary probiotic therapy and H. pylori eradication treatment versus standard therapy. Methods: Open clinical trial in patients with H. pylori infection whounder went standard eradication therapy or supplemented with probiotics for 14 days. In bothgroups, quality of life was measured with SF-36 before, at the end and 15 days after treatment. It was compared with χ², Student’s T, Wilcoxon and Mann-Whitney's U tests. Results: 50 patients were included in each group; Group with probiotics obtained quality of life scores of 41.5 ± 9.3 and 88.4 ± 10.0 at the beginning and end of follow-up (p‹0.001)while without probiotics 36.2 ± 2.8 and 92.4 x 6.8 respectively (p‹). The difference at the end of the treatment was 4.1 points higher with probiotics (p=0.039) and in the follow-up done 15 days after 4.0 higher without probiotics (p=0.071). Conclusions: Therapeutics eradication of H. pylori with or without probiotics improves quality of life at the end of treatment of 14 days and the effect continues with increment 15 days later. Probiotic supplementation shows trend to get higher quality of life than standard eradication management at the end of treatment, however, this difference is not preserved 15 days later.


REFERENCES

  1. Kusters J, van Villet. A, Kulpers E.; Pathogenesis of Helicobacter pylori Infection; Department of Gastroenterology and Hepatology, Erasmus MC—University Medical Center, Rotterdam, The Netherlands; American Society for Microbiology; 2006; Págs. 449–490.

  2. García J, Alarcón T, López M; La infección por Helicobacter pylori; Servicio de Microbiología, Hospital Universitario de La Princesa Madrid; Biopress.net; 2003; 8.

  3. Dunn B; et al; Helicobacter pylori; American Society for Microbiology; Clinical Microbiology Reviews. 1997; 10: 720–741.

  4. Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: Current and future insights. World J Clin Cases. 2016; 16 (1): 5-19.

  5. Yepes C, Rodríguez A, Ruíz A, Ariza B. Resistencia antibiótica del Helicobacter pylori en el Hospital Universitario San Ignacio de Bogotá. Act Med Col 2008; 31(1): 11-14.

  6. Koretz, R (MD); Probiotics, Critical illness, and methodologic bias; Nutrition in Clinical Practice. 2009; 24 (1): 45–49.

  7. Malfertheiner P, Megraud F, Morain CAO, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2017; 66: 6-30.

  8. Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J ClinPharmTher 2009; 34: 41-53

  9. Albornoz V; Linfoma gástrico MALT: factores de riesgo y pronóstico; GastrLatinoam 2003; 14 (3): 200-205

  10. Lara-Villoslada F. Efectos beneficiosos en niños sanos del consumo de un producto lácteo que contiene dos cepas probióticas. Lactobacilluscoryniformis CECT5711 y lactobacillusgasseri CECT5714. Nutrición hospitalaria, 2007; 22(4): 496–502.

  11. Guarner F. Papel de la flora intestinal en la salud y en la enfermedad. Nutrición hospitalaria, 2007; 22 (supl.2): 14 – 19.

  12. Lee Phillips M. Reacción visceral: Efectos sobre la microbiota humana; noticias de salud ambiental. Salud pública de México, 2009; 51 (4): 342 – 352.

  13. Bumjo O, Kim BS, Kim JW, Kim JS, Koh SJ, Kim BG, et al. The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. Helicobacter, 2016; 21 (3): 165-174.

  14. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment PharmacolTher. 2007; 25: 155-168.

  15. Dang Y, Reinhardt JD, Zhou X, Zhang G. The Effect of Probiotics Supplementation on Helicobacter pylori Eradication Rates and Side Effects during Eradication Therapy: A Meta-Analysis. Plos One. 2014; 9 (11): e111030, doi:10.1371/journal.pone.0111030.

  16. Zhang MM, Qian W, Qin YY, He J, Zhou YH. Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis. Worl J Gastroenterol. 2015; 21 (14): 4345-4357.

  17. DN Andreev, DT Dichev, IV Mays, (2017) Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. TerapevticheskiiArkhiv. 2017; 89 (2): 84-90.

  18. Zheng X, Lyu L, Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: Evidence from a meta-analysis. Rev EspEnferm Dig. 2013; 105 (8): 445-453.

  19. Lu M, Yu S, Deng J, Yan Q, Yang C, Xia G, Zhou X, Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE. 2016; 11 (10): e0163743, doi:10.1371/journal.pone.0163743

  20. Du YQ, Su T, Fan JG, Lu YX, Zheng P, Li XH, Guo CY, Xu P, Gong YF, Li ZS. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. Worl J Gastroenterol. 2012; 18 (43): 6302-6307.

  21. Myllyluoma E, Veijola L, Ahlroos T, Tynkkynen S, Kankuri E, Vapaatalo H, Rautelin H, Korpela R. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy – a placebo‐controlled, double‐blind randomized pilot study. Aliment PharmacolTher. 2005; 21: 1263-1272.

  22. Valdovinos MA, Montijo E, Abreu AT, Heller S, González-Garay A, Bacarrez D, et al. Consenso mexicano sobre probióticos en gastroenterología. Rev Gastroenterología Mex. 2017; 82 (2): 156-178.

  23. Sánchez-Delgado J, García-Iglesias P, Tito L, Puig I, Planella M, Gene E, et al. Actualización en el manejo de la infección por Helicobacter pylori. Documento de posicionamiento de la Societat Catalana de Digestologia. GastroenterolHepatol. 2018; 41(4): 272-280

  24. Álvarez-Calatayud G, Pérez-Moreno J, Tolín-Hernani M, Sánchez-Sánchez C. Recomendacionespara el empleo de probióticos en la diarrhea en la infancia. ActaPediatr Esp. 2017; 75 (5-6): 56 – 60

  25. Sebastían-Domingo JJ. Revisión del papel de los probióticos en la patología gastrointestinal deladulto. Gastroenterología y Hepatología, 2017; 40 (417-429).

  26. Barker AK, Duster M, Valentine S, Hess T, Archbald-Pannone L, Guerrant R, et al. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). J AntimicrobChemother, 2017; 72: 3177 – 3180

  27. McFarland LV, Goh S. Are probiotics and prebioticseffective in theprevention of travellers’ diarrhea: A systematicreview and meta-analysis. Travel Medicina and InfectiousDisease, 2019; 27: 11 – 19

  28. Vinaccia-Alpi S, Quiceno JM. Calidad de vida relacionada con la salud y enfermedad crónica: estudios colombianos. Psychologia, avances de la disciplina. 2012; 6 (1): 123 – 136.

  29. Duran-Arenas L, Gallegos-Carrillo K, Salinas-Escudero G, Martínez-Salgado H. Hacia una base normativa mexicana en la medición de calidad de vida relacionada con la salud, mediante Formato Corto 36. Salud pública de Mex. 2004; 46 (4): 306-315.

  30. Sánchez-Aragón R, García Meraz M, Martínez-Trujillo BD. Encuesta de Salud SF-36: Validación en Tres Contextos Culturales de México. Rev Iberoamericana de Diagnóstico y Evaluación. 2017; 3 (45): 5-16.

  31. Sugrañes-Montalván A, Barreto-Suárez E, Nicolau-Pestana E, Quesada-Leyva L. Relación entre infección por Helicobacter pylori y urticaria crónica. RevAlergMex. 2017; 64 (4): 396-402.

  32. Taguchi H, Kanmura S, Maeda T, Iwaya H, Arima S, Sasaki F, et al. Helicobacter pylori eradication improves the quality of life regardless of the treatment outcome A multicenter prospective cohort study. Medicine. 2017; 96: 52 (e9507). Disponibleenhttp://dx.doi.org/10.1097/MD.0000000000009507.

  33. Simian D, Quera R. Manejo integral de la enfermedad inflamatoria intestinal: más allá de una terapia farmacológica adecuada. RevMed Chile. 2016; 144 (4): 488-495.

  34. Bektas M, Soykan I, Altan M, Alkan M, Özden A. The effect of Helicobacter pylori eradication on dyspeptic symptoms, acid reflux and quality of life in patients with functional dyspepsia. European J of Internal Medicine, 2009; 20: 419-423.




2020     |     www.medigraphic.com